The role of FOXP3 in non-small cell lung cancer and its therapeutic potentials
- 14 December 2022
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 241, 108333
Abstract
No abstract availableKeywords
Funding Information
- International Cooperation and Exchange Programme (82272986)
- National Natural Science Foundation of China
This publication has 93 references indexed in Scilit:
- Searching for the Achilles Heel of FOXP3Frontiers in Oncology, 2013
- Foxp3 overexpression decreases sensitivity to chemotherapy in mouse Lewis lung cancer cellsMolecular Medicine Reports, 2012
- FOXP3 expression in tumor cells and implications for cancer progressionJournal of Cellular Physiology, 2012
- Non-coding RNAs in human diseaseNature Reviews Genetics, 2011
- Signalling through FOXP3 as an X-linked tumor suppressorThe International Journal of Biochemistry & Cell Biology, 2010
- Absence of Leucine Zipper in the Natural FOXP3Δ2Δ7 Isoform Does Not Affect Dimerization but Abrogates Suppressive CapacityPLOS ONE, 2009
- Forced overexpression of either of the two common human Foxp3 isoforms can induce regulatory T cells from CD4+CD25– cellsEuropean Journal of Immunology, 2008
- FOXP3 Is an X-Linked Breast Cancer Suppressor Gene and an Important Repressor of the HER-2/ErbB2 OncogeneCell, 2007
- Epigenetic Control of the foxp3 Locus in Regulatory T CellsPLOS Biology, 2007
- The role of autophagy in cancer development and response to therapyNature Reviews Cancer, 2005